EGFR and neoplasm: Plasma detection of the original EGFR-sensitizing mutation was more challenging in samples from patients with tumor progression exclusively at the brain level, compared with patients diagnosed as having disease progression in other locations (EGFR detection rate of 61.5% vs. 76.3%, respectively).